Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 17 Jul 2018 |
| Genmab Enters Strategic Partnership with Immatics to Discover and Develop Next Generation Bispecific Cancer Immunotherapies | 12 Jul 2018 |
| Genmab A/S has published its Articles of Association | 4 Jul 2018 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 3 Jul 2018 |
| HuMax®-AXL-ADC Progress Triggers Milestone Payment to Seattle Genetics | 29 Jun 2018 |